Signant Health Adds Computerized Adaptive Tests
PROMIS CATs use a dynamic approach that aims to measure concepts, such as fatigue or physical functioning, with fewer questions.
Signant Health announced its ability to deliver computerized adaptive tests (CATs) in clinical trials utilizing its Patient-Reported Outcome Measure Information System (PROMIS). Fully hosted by Signant Health, PROMIS CATs can be implemented and incorporated into its company’s eCOA solution alongside conventional PROMs. In contrast to PROMS, which typically use questionnaires containing a fixed number of questions, PROMIS CATs use a dynamic approach that aims to measure concepts, such as fatigue or physical functioning, with fewer questions while maintaining precision via statistical model.
Learn more about the digital health measures and PROMIS CATS.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
